EDIT (Editas Medicine) FFO


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $2.81
GF Value $1.92
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine FFO?

FFO (Funds from operations) only applies to REITs.

EDIT
51GF Score
Editas Medicine Inc EDIT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.81 is trading 46.1% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • FFO:
  • GF Value™: $1.92 vs. price of $2.81 (46.1% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.81
Price
$1.92
GF Value